- 註冊時間
- 2023-5-6
- 精華
- 在線時間
- 小時
- 米币
-
- 最後登錄
- 1970-1-1
|
發表於 2025-1-4 03:09:28
|
顯示全部樓層
RESPONSE OF MICROPENIS TO TOPICAL TESTOSTERONE AND+ S2 i% i: q8 O% e( K( C V$ M3 w
GONADOTROPIN) B @6 T. k" N& y% v) h7 w$ }5 k
RICHARD C. KLUGO* AND JOSEPH C. CERNY
# p& a0 [* ?# p" y' B8 QFrom the Division of Urology, Henry Ford Hospital, Detroit, Michigan
4 {4 `0 }# _. ^, p3 _ABSTRACT
% v, z: j8 s+ k6 \6 L$ F- IFive patients were treated with gonadotropin and topical testosterone for micropenis associated
5 i. B& q: C0 C! S- i; E. \ @" xwith hypothalamic hypogonadotropic hypogonadism. All patients received 1,000 units of gonado-9 d" x' ]' G+ [, l
tropin weekly for 3 weeks, with a 6-week interval followed by 10 per cent topical testosterone; b, Q2 N L4 R n- `
cream twice daily for 3 weeks. Serum testosterone levels were measured and remained equivalent
5 N" o' [% Z) x) H- N# j+ bfor both modes of therapy. Average penile growth response with gonadotropin was 14.3 per cent
6 b% ^" U. s x- C! X! ?0 eincrease in length and 5.0 per cent increase of girth. Topical testosterone produced an average7 Q4 R" B N0 d4 c( K& f, h5 n% O4 Y
increase of 60 per cent in penile length and 52. 9 per cent in girth. The greatest growth response
' v/ w2 w8 q! y- J; E2 {2 `. ]1 joccurred in prepuberal male subjects with a minimal response in postpuberal male subjects. This
" I4 U7 n: e7 l; c) z$ o1 pstudy suggests that 10 per cent topical testosterone cream twice daily will produce effective penile" I, c3 E) l/ d' I4 k! |! z+ e
growth. The response appears to be greater in younger children, which is consistent with previ-
2 N4 m) i7 J- ^ously published studies of age-related 5 reductase activity.
3 Y* K1 ]( H8 i% c8 s. h O$ oChildren with microphallus regardless of its etiology will- u3 `8 v# A! q3 o: ^$ k; g
require augmentation or consideration for alteration of exter-
% s4 o5 }3 Q- p+ J( b6 V5 e& _nal genitalia. In many instances urethroplasty for hypo-
! `& M' P7 ~: g( Bspadias is easier with previous stimulation of phallic growth.2 p( f" k, G) ~
The use of testosterone administered parenterally or topically
3 S4 ?" Z- x5 V" Y$ T$ `has produced effective phallic growth. 1- 3 The mechanism of# o4 A6 ~& h4 M
response has been considered as local or systemic. With this. a1 u; M6 n: f
in mind we studied 5 children with microphallus for response- Z9 O2 N* k8 A0 y( x
to gonadotropin and to topical testosterone independently.
; R+ {1 B( o% GMATERIALS AND METHODS
' `4 j' M& ?0 ^, G0 gFive 46 XY male subjects between 3 and 17 years old were0 [ f" R' O9 w! q6 L" Y
evaluated for serum testosterone levels and hypothalamic
2 n2 l9 q8 X' g8 [6 Hfunction. Of these 5 boys 2 were considered to have Kallmann's6 ~# o H, f7 p& c j
syndrome, 1 Prader-Willi syndrome and 2 idiopathic hypotha-
9 |* A) p# _; u( flamic deficiency. After evaluation of response to luteinizing4 y9 E: b& Z7 F( j% O2 c1 l7 Q
hormone-releasing hormone these patients were treated with
' a7 ]- C; u5 h. z6 O1,000 units of gonadotropin weekly for 3 weeks. Six weeks. H( a7 o d+ ~/ W+ C0 C
after completion of gonadotropin therapy 10 per cent topical
$ G) a- x' o9 N: Dtestosterone was applied to the phallus twice daily for 3 weeks.- Z7 n j$ d) e" m+ N) X
Serum testosterone, luteinizing hormone and follicle-stimulat-. B" ?2 J V8 L- J J
ing hormone were monitored before, during and after comple-* ^! t0 a9 m. P( e0 o+ A
tion of each phase of therapy. Penile stretch length was
; q7 D$ d7 e* W3 E# fobtained by measuring from the symphysis pubis to the tip of
- q/ Q$ ?* f; f% X* R8 pthe glans. Penile circumferential (girth) measurements were/ }; b8 r( r5 Y0 i# ]6 P
obtained using an orthopedic digital measuring device (see
2 M/ f* y/ |$ Tfigure).
/ j8 x+ s4 L; ^/ ZRESULTS- H" M0 b; y- e' o: Q: o
Serum testosterone increased moderately to levels between
0 B+ v: L' G( r: r4 J ~50 and 86 ng./dl. with gonadotropin stimulation. Serum testos-
! q: J5 Y; X1 ^" X' X! V' U; o+ Eterone levels with topical testosterone remained near pre-
: c3 p! s( m. u% O0 A# }' wtreatment levels (35 ng./dl.) or were elevated to similar levels; }; p! c! i1 p( V8 Q0 U9 U) ~
developed after gonadotropin therapy (96 ng./dl.). Higher5 E$ _* o) \6 O1 R0 O- f' b
serum levels were noted in older patients (12 and 17 years old),
/ a$ W! `* D. }) L' Ewhile lower levels persisted in younger patients (4, 8, and 10% S% q* T/ v4 |4 k; o
years old) (see table). Despite absence of profound alterations
& P) \& a5 R! P( N; |of serum testosterone the topical therapy provided a greater
+ g- G- T' |7 s8 d qAccepted for publication July 1, 1977. ·% S! D8 \( Y5 \
Read at annual meeting of American Urological Association,( Z2 W* `. |2 `8 x+ \2 u
Chicago, Illinois, April 24-28, 1977.
6 v& Z! A% W# {/ B: ~8 M1 \* Requests for reprints: Division of Urology, Henry Ford Hospital,$ m+ T$ r2 P( [& k$ d
2799 W. Grand Blvd., Detroit, Michigan 48202.1 @8 G0 T1 s( X: j6 P7 y. A( W8 q1 y
improvement in phallic growth compared to gonadotropin.
: _0 t, ?- W1 ?# wAverage phallic growth with gonadotropin was 14.3 per cent
& H; F9 ^6 C& o9 }increase in length and 5.0 per cent increase of girth. Topical
9 r- a/ U8 N1 x/ `+ E" u. ztestosterone produced a 60.0 per cent increase of phallic length; D! @: P, T& ?$ |3 Y. G- r5 s
and 52.9 per cent increase of girth (circumference). The1 y* [$ i/ g1 X& V. i
response to topical testosterone was greatest in children be-- l( x6 L' \6 G6 X! `" E
tween 4 and 8 years old, with a gradual decrease to age 17% F9 N; {( F2 t6 a% {; t* i: Q- m
years (see table).8 a, c; u' K6 H: X* I
DISCUSSION
& l9 h0 n: @5 _3 ^) LTopical testosterone has been used effectively by other; q0 A6 k! r7 q1 b7 {. c) ~
clinicians but its mode of action remains controversial. Im-
( e# y, r: }4 Wmergut and associates reported an excellent growth response
9 O! j8 e5 k. Nto topical testosterone with low levels of serum testosterone,
C; J' S/ ~. s7 t3 x# ]$ ?suggesting a local effect.1 Others have obtained growth re-
8 z8 ]2 Z. B6 m1 H1 G- Isponse with high. levels of serum testosterone after topical4 d$ y1 Z( I; d6 i# @6 |. V
administration, suggesting a systemic response. 3 The use of% X' G2 f$ `/ a3 T% r3 s C; b s
gonadotropin to obtain levels of serum testosterone compara-" Y6 W6 J/ ]5 j( o4 K; a% E
ble to levels obtained with topical testosterone would seem to
6 D) d& e6 [3 q9 R+ _' {6 g# \provide a means to compare the relative effectiveness of
! J& t5 H& _) J" c6 P0 Ktopical testosterone to systemic testosterone effect. It cer-/ Y3 p* |3 H6 F+ Q& r
tainly has been established that gonadotropin as well as par-6 k9 k5 }# v6 \7 b2 F5 s) ^
enteral testosterone administration will produce genital8 C- i7 p, y" f+ Y* z1 J
growth. Our report shows that the growth of the phallus was9 R& a+ h! F2 Q4 ~
significantly greater with topical applications than with go-3 @; G6 u% ?7 y9 p8 I& @
nadotropin, particularly in children less than 10 years old./ }) J ^9 E* a7 N7 E3 b
The levels of serum testosterone remained similar or lower3 v) C1 \) B( \7 X; d
than with gonadotropin during therapy, suggesting that topi-$ M/ M9 W: Z6 R
cal application produces genital growth by its local effect as
) Z7 {3 `$ j8 G V0 _0 O6 Pwell as its systemic effect.3 K2 p# K$ P% \9 }( r& _- ]
Review of our patients and their growth response related to5 j. d; @1 Q* P* _! M' J
age shows a greater growth response at an earlier age. This is3 j! ^( y! s1 E1 X
consistent with the findings of Wilson and Walker, who) y( Z9 F8 y( Z
reported an increased conversion of testosterone to dihydrotes-
/ |7 Q9 f' ^) k. H+ b4 mtosterone in the foreskin of neonates and infants.4 This activ-
& K" ^0 L9 t5 h5 g5 {4 `ity gradually decreases with age until puberty when it ap-: M$ U( r6 L' I3 H: B2 ]
proaches the same level of activity as peripheral skin. It may
/ n( ^& i$ \4 X* Lwell be that absorption of testosterone is less when applied at6 }! R! Q! H: J3 y) T( v
an earlier age as suggested by lower serum levels in children
! g& j1 ?$ R# o9 ~4 b% eless than 10 years old. This fact may be explained by the
1 ] M! C$ h# x3 f5 hgreater ability of phallic skin to convert testosterone to dihy-) n+ ]: y; \& ?! V; b9 F
drotestosterone at this age. Conversely, serum levels in older
% m1 d% U' F) ]: Vpatients were higher, possibly because of decreased local
' e" e! o/ R+ L1 T( q5 I7 J. X667
6 e4 N" G1 R q& l% V668 KLUGO AND CERNY
. T3 L6 b& E* X9 |- g: FPt. Age
3 K. J g5 [! } r3 Q5 |(yrs.)% v. c) Z7 w1 ?5 S2 E/ E' T1 U
Serum Testosterone Phallus (cm.) Change Length
9 \8 R/ G' T, w3 n" q7 @0 r(ng./dl.) Girth x Length (%)
! f! ?) B* Q. J# U$ k/ ?2 `+ o6 G0 d4. o" a9 y# H) @, L) w
8
) e1 ?5 @. J7 J2 B# d10
( [8 l% F1 ^, ]% J12
# Y+ D8 U' K) }& K17
7 q9 W6 }* d, t, \9 {1 JGonadotropin
3 f( b: `: U8 y2 e6 s; u71.6 2.0 X 3 16.6
) Q5 k; }# C/ V! |50.4 4.0 X 5.0 20.0
3 b2 i1 |( B9 U* S) d" b5 g22.0 4.5 X 4.0 25.0. }( n: R% K/ D0 D1 K' S% M9 r
84.6 4.0 X 4.5 11.1
* A ?9 V7 B6 F% Y! m* i, ]85.9 4.5 X 5.5 9.0
) F3 O! E. L" E" uAv. 14.3
2 [$ d2 c- U: `9 k- o45 F# H% ^6 s" L! i8 Z
8
" Q) [7 k9 J- ]1 k+ u D' W* n. D103 i- p! j% q5 {# O( E5 h
12
' [+ v# d+ u5 ^6 f' Y4 {7 t' g17
$ L/ {: ]5 f5 p5 _* N5 ]Topical testosterone+ m; H9 p1 R0 P$ L
34.6 4.5 X 6.5 85
& b0 f# y' A- A" b, W' y- a: Y38.8 6.0 X 8.5 70
) W/ e" ^1 t/ N$ e40.0 6.0 X 6.5 62.56 M2 M0 q6 p" V6 U. u% S
93.6 6.0 X 7.0 55.5
9 f. g9 m, K/ v95.0 6.5 X 7.0 27.2: [8 o, B, P( e1 U+ D f
Av. 60.02 v- P ~* ^9 m6 N8 k
available testosterone. Again, emphasis should be placed on
# a/ D1 v7 m, ]) k2 nearly therapy when lower levels of testosterone appear to
2 e! x3 \% l& r3 l9 z6 _2 Zprovide the best responses. The earlier therapy is instituted) V3 Y1 q- H9 p j* i
the more likely there will be an excellent response with low
, W& `0 ~, ~1 ]# |3 cserum levels. Response occurs throughout adolescence as" H. `- B, D- {5 i
noted in nomograms of phallic growth. 7 The actual response9 r% U% G: G2 b$ r0 A
to a given serum level of testosterone is much greater at birth
4 r' F- O/ B( mand gradually decreases as boys reach puberty. This is most" u+ L* ] X+ R, y! r
likely related to the conversion of testosterone to dihydrotes-
6 z2 p$ M* w8 V5 Z% Z6 Xtosterone and correlates well with the studies of testosterone5 ^; u. J7 U4 u* {3 Z' p
conversion in foreskin at various ages., E: L+ h7 f% H" H" P# j( Z6 J
The question arises regarding early treatment as to whether5 j3 B/ q1 @* f* U1 n P* `
one might sacrifice ultimate potential growth as with acceler-
9 `" C- F* O" `) x& v* t! T3 |ated bone growth. The situation appears quite the reverse
) G) H+ n& H" J7 e& D& Wwith phallic response. If the early growth period is not used
8 \5 k/ z$ Q5 g1 @: V6 C" Jwhen 5a reductase activity is greatest then potential growth
( i8 C6 U4 p: Imay be lost. We have not observed any regression of growth9 W% p5 R5 O9 p1 i
attained with topical or gonadotropin therapy. It may well
3 e; \) |+ r' Ebe that some patients will show little or no response to any: A1 d8 l$ w. }. o5 c
form of therapy. This would suggest a defect in the ability to9 L+ T; u" h' ], {: X+ j
convert testosterone to dihydrotestosterone and indicate that7 O3 S3 }# K- Q, i& b3 ^" a5 D) I& B
phallic and peripheral skin, and subcutaneous tissue should% z0 ^/ l' L o% `3 ^
be compared for 5a reductase activity.
. Y5 I% \1 T0 S2 `8 {A, loop enlarges to measure penile girth in millimeters. B,2 x4 z* Q3 C w8 E- y9 i1 U
example of penile girth computed easily and accurately.* Y' d; l' l, K2 ^0 g0 N. C% S
conversion of testosterone to dihydrotestosterone. It is in this
( E) y! }9 f& V* B P9 [5 Colder group that others have noted high levels of serum
* i0 R1 y4 n( p% C' `testosterone with topical application. It would also appear' c5 l) h8 Q+ `& O
that phallic response during puberty is related directly to the3 f8 S- Y5 y' ~& h. G2 V2 V
serum testosterone level. There also is other evidence of local1 h* v* g; R* D w6 }# B0 r8 Y- q
response to testosterone with hair growth and with spermato-8 u: k1 Q4 a$ u1 N
genesis. 5• 6# k/ ]9 {% u5 r; R
Administration of larger doses of gonadotropin or systemic0 A- s2 M* }. |, I+ q ]5 |
testosterone, as well as topical applications that produce) q) s# T: P* K8 ]" w
higher levels of serum testosterone (150 to 900 ng./dl.), will
: p" L3 c# M) Z& |also produce phallic growth but risks accelerated skeletal
7 S# K5 [' |3 F0 omaturation even after stopping treatment. It would appear, k! |* o6 k1 \2 V' R7 D" H y
that this may be avoided by topical applications of testosterone
6 c: p. J5 ^, v; F, {+ Qand monitoring of serum testosterone. Even with this control
+ ^, U1 T8 f8 ithe duration of our therapy did not exceed 3 weeks at any
7 C; a( g0 u- ^" y# t: p6 q$ |time. It is apparent that the prepuberal male subject may, e7 u3 K7 c% @, G! n/ a
suffer accelerated bone growth with testosterone levels near n! `- l) r& Y( J
200 ng./dl. When skeletal maturation is complete the level of' @2 I+ W" Q) d0 v3 T* f) n
serum testosterone can be maintained in the 700 to 1,300 ng./
, A6 I. r3 Z/ Edl. range to stimulate phallic growth and secondary sexual
" d5 G9 h7 M5 }- q/ D# cchanges. Therefore, after skeletal maturation parenteral tes-
! t3 ] Y$ J% l X) T0 |0 ^7 Dtosterone may be used to advantage. Before skeletal matura-
, D* P; U( ?) X$ `# L8 Xtion care must be taken to avoid maintaining levels of serum
, S0 w7 Q0 o- Ntestosterone more than 100 ng./dl. Low-dose gonadotropin
- J# Q# m: p7 U" `+ o sdepends upon intrinsic testicular activity and may require
& _2 k: D0 {. U/ x+ ?8 o9 k5 K! Qprolonged administration for any response.
! @1 j F$ @2 n: zAlternately, topical testosterone does not depend upon tes-
" C1 Z! q q# h' J% z7 `ticular function and may provide a more constant level of
7 h z8 E9 M3 a0 @ C& tREFERENCES
# Y+ V, L" F( Y! g- X1. Immergut, M., Boldus, R., Yannone, E., Bunge, R. and Flocks,- C; X+ m8 L0 N* E5 A
R.: The local application of testosterone cream to the prepub-
O% K3 b) w' A4 b! n5 Wertal phallus. J. Urol., 105: 905, 1971.
8 B4 w ]0 J7 k" K+ F, ?2. Guthrie, R. D., Smith, D. W. and Graham, C. B.: Testosterone
. l$ C" Q/ Q/ H# R0 `treatment for micropenis during early childhood. J. Pediat.,
/ K* }% _; L7 K0 i. F" a83: 247, 1973., M7 u( A- b$ p9 g ?1 N& M, P7 c
3. Jacobs, S. C., Kaplan, G. W. and Gittes, R. F.: Topical testoster-2 [ Y+ }1 t5 P
one therapy for penile growth. Urology, 6: 708, 1975.7 C h" M8 R. ]! n+ y9 w7 J$ B
4. Wilson, J. D. and Walker, J. D.: The conversion of testosterone- Q6 _) n8 \9 g4 w' ]6 B4 h
to 5 alpha-androstan-17 beta-01-3-one (dihydrotestosterone) by
% s, ~* l. i0 a8 _# wskin slices of man. J. Clin. Invest., 48: 371, 1969.
% G5 ?/ d: b" U. H5. Papa, C. M. and Klingman, A. M.: Stimulation of hair growth
, d* K$ ]# ~ a& sby topical application of androgens. J.A.M.A., 191: 521, 1965.* a. \/ @/ Q; E+ j. ^, ?
6. Gittes, R. F., Smith, G., Conn, C. A. and Smith, F.: Local- i" r; z$ ~6 u. b0 f
androgenic effect of interstitial cell tumor of the testis. J.$ T& |* n! |" o! q4 X0 b
Urol., 104: 774, 1970.
% P3 n3 C7 b' }/ B8 N m7. Schonfeld, W. A. and Beebe, G. W.: Normal growth and varia-
- K8 ]4 m; Q. _* ntion in the male genitalia from birth to maturity. J. Urol., 48: |
|